首页> 美国卫生研究院文献>Elsevier Sponsored Documents >Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies Parkinsons disease and Dementia with Lewy bodies
【2h】

Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies Parkinsons disease and Dementia with Lewy bodies

机译:验尸后脑脊液中α-突触核蛋白的水平在多系统萎缩症中升高并将其与其他α-突触核病帕金森氏病和路易体痴呆区分开来

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Differentiating clinically between Parkinson's disease (PD) and the atypical parkinsonian syndromes of Progressive supranuclear palsy (PSP), corticobasal syndrome (CBS) and multiple system atrophy (MSA) is challenging but crucial for patient management and recruitment into clinical trials. Because PD (and the related disorder Dementia with Lewy bodies (DLB)) and MSA are characterised by the deposition of aggregated forms of α-synuclein protein (α-syn) in the brain, whereas CBS and PSP are tauopathies, we have developed immunoassays to detect levels of total and oligomeric forms of α-syn, and phosphorylated and phosphorylated oligomeric forms of α-syn, within body fluids, in an attempt to find a biomarker that will differentiate between these disorders. Levels of these 4 different forms of α-syn were measured in post mortem samples of ventricular cerebrospinal fluid (CSF) obtained from 76 patients with PD, DLB, PSP or MSA, and in 20 healthy controls. Mean CSF levels of total and oligomeric α-syn, and phosphorylated α-syn, did not vary significantly between the diagnostic groups, whereas mean CSF levels of phosphorylated oligomeric α-syn did differ significantly (p < 0.001) amongst the different diagnostic groups. Although all 4 measures of α-syn were higher in patients with MSA compared to all other diagnostic groups, these were only significantly raised (p < 0.001) in MSA compared to all other diagnostic groups, for phosphorylated oligomeric forms of α-syn. This suggests that this particular assay may have utility in differentiating MSA from control subject and patients with other α-synucleinopathies. However, it does not appear to be of help in distinguishing patients with PD and DLB from those with PSP or from control subjects. Western blots show that the principal form of α-syn within CSF is phosphorylated, and the finding that the phosphorylated oligomeric α-syn immunoassay appears to be the most informative of the 4 assays would be consistent with this observation.
机译:在临床上区分帕金森氏病(PD)和渐进性核上性麻痹(PSP),皮质基底膜综合症(CBS)和多系统萎缩(MSA)的非典型帕金森综合症具有挑战性,但对于患者管理和招募进入临床试验至关重要。由于PD(以及相关的路易体痴呆(DLB)疾病)和MSA的特征是聚集形式的α-突触核蛋白(α-syn)在大脑中沉积,而CBS和PSP是Tauopathies,因此我们开发了免疫分析检测体液中α-syn的全部和寡聚形式以及磷酸化和磷酸化的α-syn寡聚形式的水平,以试图找到可区分这些疾病的生物标志物。在从76名PD,DLB,PSP或MSA患者中获得的心室脑脊液(CSF)的死后样本中以及20位健康对照中测量了这4种不同形式的α-syn的水平。在诊断组之间,总的和寡聚的α-syn的平均CSF水平没有显着差异,而在不同的诊断组之间,磷酸化的寡聚的α-syn的平均CSF水平却没有显着差异(p <0.001)。尽管MSA患者的所有4种α-syn指标均高于所有其他诊断组,但对于磷酸化的低聚形式的α-syn,与所有其他诊断组相比,MSA中这些指标仅显着升高(p <0.001)。这表明该特定测定法可用于将MSA与对照受试者和患有其他α-突触核蛋白病的患者区分开。然而,将PD和DLB患者与PSP患者或对照对象区分开来似乎没有帮助。蛋白质印迹显示,CSF中α-syn的主要形式被磷酸化,而磷酸化的寡聚α-syn免疫测定法似乎是这四种测定方法中最有用的发现,将与该观察结果一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号